Theodore J. Anfinson, MD: Akathisia, Panic, Agoraphobia, and Major Depression Following Brief Exposure to Metoclopramide

Name: Theodore J. Anfinson, MD: Akathisia, Panic, Agoraphobia, and Major Depression Following Brief Exposure to Metoclopramide
SKU: 3251
Availability: InStock

$30.00

Want a discount? Become a member by purchasing Psychopharmacology Bulletin Subscription - Individual!

Categories: Psychopharmacology Bulletin, VOL 36 No. 1 Articles Tags: anxiety, benzamide, depression, extrapyramidal-symptoms, metoclopramide, theodore-j-anfinson

Description

Theodore J. Anfinson, MD: Akathisia, Panic, Agoraphobia, and Major Depression Following Brief Exposure to Metoclopramide

Description

Theodore J. Anfinson, MD

COMPLICATED CASE HISTORIES

Akathisia, Panic, Agoraphobia, and Major Depression Following Brief Exposure to Metoclopramide

Theodore J. Anfinson, MD

Donald S. Robinson, MD: Treatment Effects of Selegiline Transdermal System on Symptoms of Major Depressive Disorder: A Meta-Analysis of Short-Term, Placebo-Controlled, Efficacy Trials

Robert MA Hirschfeld, MD: Defining the Clinical Course of Bipolar Disorder: Response, Remission, Relapse, Recurrence, and Roughening

Efficacy of Omega-3 Fatty Acids in Mood Disorders

Advancing the Treatment of Mood and Anxiety Disorders: The First 10 Years’ Experience with Paroxetine

Theodore J. Anfinson, MD: Akathisia, Panic, Agoraphobia, and Major Depression Following Brief Exposure to Metoclopramide

Description

Theodore J. Anfinson, MD

COMPLICATED CASE HISTORIES

Akathisia, Panic, Agoraphobia, and Major Depression Following Brief Exposure to Metoclopramide

Theodore J. Anfinson, MD

Related products

Donald S. Robinson, MD: Treatment Effects of Selegiline Transdermal System on Symptoms of Major Depressive Disorder: A Meta-Analysis of Short-Term, Placebo-Controlled, Efficacy Trials

Robert MA Hirschfeld, MD: Defining the Clinical Course of Bipolar Disorder: Response, Remission, Relapse, Recurrence, and Roughening

Efficacy of Omega-3 Fatty Acids in Mood Disorders

Advancing the Treatment of Mood and Anxiety Disorders: The First 10 Years’ Experience with Paroxetine